Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2025 (Transaction date: August 6, 2025)
Subject: Disclosure of a transaction in own shares (Share Buyback).
Key Financial Metrics and Transaction Details
This filing details a specific share repurchase transaction executed under an existing buyback program. It does not contain revenue, profit, or cash flow data for the period.
| Metric | Value |
|---|---|
| Shares Purchased (August 6, 2025) | 504,016 |
| Lowest Price Paid | 1,372.00 GBp |
| Highest Price Paid | 1,396.50 GBp |
| Volume-Weighted Average Price | 1,383.42 GBp |
| Trading Venue | London Stock Exchange (XLON) |
| Broker | Merrill Lynch International |
| Program Start Date | June 4, 2025 |
| Total Shares Purchased Since Program Start | 20,908,178 |
| Total Treasury Shares Held | 239,042,561 |
| Ordinary Shares in Issue (Excl. Treasury) | 4,076,345,924 |
| Treasury Shares as % of Voting Rights | 5.86% |
Material Changes
The filing reports a reduction in the number of shares in issue and an increase in treasury shares held by the company. The percentage of voting rights attributable to treasury shares increased to 5.86% following this transaction. No other material changes to financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The purchase was effected pursuant to a non-discretionary agreement entered into on June 4, 2025. The shares purchased are held as Treasury shares.
Risks: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's 2024 Annual Report on Form 20-F and Q2 2025 Results.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback program announced on June 4, 2025.
- Confirm the total number of shares in issue (4,076,345,924) for accurate EPS calculations.
- Review the "Risk Factors" section of the 2024 Form 20-F and Q2 2025 Results for context on forward-looking statements.
- Monitor future 6-K filings for subsequent buyback activity under the non-discretionary agreement.